

**Experiment Number:** 88148-02  
**Test Type:** 14-DAY  
**Route:** GAVAGE  
**Species/Strain:** Mouse/B6C3F1

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH  
AVERAGE SEVERITY GRADES[b]**  
**Test Compound:** 3,3',4,4'-Tetrachloroazobenzene  
**CAS Number:** 14047-09-7

**Date Report Requested:** 10/15/2014  
**Time Report Requested:** 23:44:30  
**First Dose M/F:** NA / NA  
**Lab:** MBA

**C Number:** C88148  
**Lock Date:** 01/19/1994  
**Cage Range:** All  
**Date Range:** All  
**Reasons For Removal:** All  
**Removal Date Range:** All  
**Treatment Groups:** All  
**Study Gender:** Both  
**PWG Approval Date** NONE

Experiment Number: 88148-02  
 Test Type: 14-DAY  
 Route: GAVAGE  
 Species/Strain: Mouse/B6C3F1

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH  
 AVERAGE SEVERITY GRADES[b]**  
 Test Compound: 3,3',4,4'-Tetrachloroazobenzene  
 CAS Number: 14047-09-7

Date Report Requested: 10/15/2014  
 Time Report Requested: 23:44:30  
 First Dose M/F: NA / NA  
 Lab: MBA

B6C3F1 Mouse MALE	0 MG/KG	1 MG/KG	3.2 MG/KG	10 MG/KG	32 MG/KG	100 MG/KG
<b>Disposition Summary</b>						
Animals Initially In Study	5	5	5	5	5	5
Early Deaths						
Survivors						
Terminal Sacrifice	5	5	5	5	5	5
Animals Examined Microscopically	5				5	5
<b>ALIMENTARY SYSTEM</b>						
Gallbladder	(5)	(0)	(0)	(0)	(0)	(5)
Liver	(5)	(0)	(0)	(0)	(0)	(5)
Hemorrhage, Focal	1 [1.0]					
Necrosis, Focal						1 [1.0]
Stomach, Forestomach	(5)	(0)	(0)	(0)	(0)	(5)
Stomach, Glandular	(5)	(0)	(0)	(0)	(0)	(5)
<b>CARDIOVASCULAR SYSTEM</b>						
None						
<b>ENDOCRINE SYSTEM</b>						
None						
<b>GENERAL BODY SYSTEM</b>						
None						
<b>GENITAL SYSTEM</b>						
None						
<b>HEMATOPOIETIC SYSTEM</b>						
Lymph Node, Mesenteric	(5)	(0)	(0)	(0)	(0)	(5)
Spleen	(5)	(0)	(0)	(0)	(5)	(5)
Hematopoietic Cell Proliferation						1 [1.0]
Lymph Follic, Atrophy						2 [1.5]

a - Number of animals examined microscopically at site and number of animals with lesion  
 b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

**Experiment Number:** 88148-02  
**Test Type:** 14-DAY  
**Route:** GAVAGE  
**Species/Strain:** Mouse/B6C3F1

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH  
AVERAGE SEVERITY GRADES[b]**  
**Test Compound:** 3,3',4,4'-Tetrachloroazobenzene  
**CAS Number:** 14047-09-7

**Date Report Requested:** 10/15/2014  
**Time Report Requested:** 23:44:30  
**First Dose M/F:** NA / NA  
**Lab:** MBA

<b>B6C3F1 Mouse MALE</b>	<b>0 MG/KG</b>	<b>1 MG/KG</b>	<b>3.2 MG/KG</b>	<b>10 MG/KG</b>	<b>32 MG/KG</b>	<b>100 MG/KG</b>
Thymus	(5)	(0)	(0)	(0)	(0)	(5)
INTEGUMENTARY SYSTEM						
None						
MUSCULOSKELETAL SYSTEM						
None						
NERVOUS SYSTEM						
None						
RESPIRATORY SYSTEM						
None						
SPECIAL SENSES SYSTEM						
None						
URINARY SYSTEM						
Kidney	(5)	(0)	(0)	(0)	(0)	(5)

\*\*\*END OF MALE DATA\*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion  
b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Experiment Number: 88148-02  
 Test Type: 14-DAY  
 Route: GAVAGE  
 Species/Strain: Mouse/B6C3F1

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH  
 AVERAGE SEVERITY GRADES[b]**  
 Test Compound: 3,3',4,4'-Tetrachloroazobenzene  
 CAS Number: 14047-09-7

Date Report Requested: 10/15/2014  
 Time Report Requested: 23:44:30  
 First Dose M/F: NA / NA  
 Lab: MBA

B6C3F1 Mouse FEMALE	0 MG/KG	1 MG/KG	3.2 MG/KG	10 MG/KG	32 MG/KG	100 MG/KG
<b>Disposition Summary</b>						
Animals Initially In Study	5	5	5	5	5	5
Early Deaths						
Survivors						
Terminal Sacrifice	5	5	5	5	5	5
Animals Examined Microscopically	5				5	5
<b>ALIMENTARY SYSTEM</b>						
Gallbladder	(5)	(0)	(0)	(0)	(0)	(5)
Liver	(5)	(0)	(0)	(0)	(0)	(5)
Hematopoietic Cell Proliferation						1 [1.0]
Stomach, Forestomach	(5)	(0)	(0)	(0)	(0)	(5)
Stomach, Glandular	(5)	(0)	(0)	(0)	(0)	(5)
<b>CARDIOVASCULAR SYSTEM</b>						
None						
<b>ENDOCRINE SYSTEM</b>						
None						
<b>GENERAL BODY SYSTEM</b>						
None						
<b>GENITAL SYSTEM</b>						
None						
<b>HEMATOPOIETIC SYSTEM</b>						
Lymph Node, Mesenteric	(5)	(0)	(0)	(0)	(0)	(5)
Spleen	(5)	(0)	(0)	(0)	(5)	(5)
Hematopoietic Cell Proliferation						4 [1.0]
Lymph Follic, Atrophy						3 [1.0]
Thymus	(5)	(0)	(0)	(0)	(5)	(5)

a - Number of animals examined microscopically at site and number of animals with lesion  
 b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

**Experiment Number:** 88148-02  
**Test Type:** 14-DAY  
**Route:** GAVAGE  
**Species/Strain:** Mouse/B6C3F1

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH  
AVERAGE SEVERITY GRADES[b]**  
**Test Compound:** 3,3',4,4'-Tetrachloroazobenzene  
**CAS Number:** 14047-09-7

**Date Report Requested:** 10/15/2014  
**Time Report Requested:** 23:44:30  
**First Dose M/F:** NA / NA  
**Lab:** MBA

<b>B6C3F1 Mouse FEMALE</b>	<b>0 MG/KG</b>	<b>1 MG/KG</b>	<b>3.2 MG/KG</b>	<b>10 MG/KG</b>	<b>32 MG/KG</b>	<b>100 MG/KG</b>
Atrophy						2 [1.0]
Hemorrhage	2 [1.0]					1 [1.0]
<b>INTEGUMENTARY SYSTEM</b>						
None						
<b>MUSCULOSKELETAL SYSTEM</b>						
None						
<b>NERVOUS SYSTEM</b>						
None						
<b>RESPIRATORY SYSTEM</b>						
None						
<b>SPECIAL SENSES SYSTEM</b>						
None						
<b>URINARY SYSTEM</b>						
Kidney	(5)	(0)	(0)	(0)	(0)	(5)

**\*\* END OF REPORT \*\***

a - Number of animals examined microscopically at site and number of animals with lesion  
b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)